Meldungen zum Thema Medizin

Abonnieren Sie alle Meldungen zum Thema Medizin

25.04.2018 – 13:10

Constance Therapeutics and Kanabo Research

Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Tel Aviv, Israel (ots/PRNewswire) - Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical cannabis extraction company. (Photo: ...

23.04.2018 – 12:00

Grünenthal Group

Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)

Aachen (ots) - Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal's research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and ...

23.04.2018 – 01:02

Inceptua

Creation of Inceptua Clinical Trial Services Marks New Era for the Company

Luxembourg (ots/PRNewswire) - Inceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including Clinical Trial Services, Medicines Access and Commercial Products will be marketed under the same corporate ...

20.04.2018 – 07:01

UCB Pharma

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

Brussels (ots/PRNewswire) - - Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug ...

16.04.2018 – 08:00

FDI World Dental Federation

FDI white paper and practical guide address the global burden of periodontal disease

Geneva (ots) - FDI World Dental Federation published two resources - a white paper and a practical guide - as part of its Global Periodontal Health Project (GPHP), which aims to bring attention to periodontal health as a priority area for policy worldwide. "Periodontal disease - or gum disease as it is often better known - is one of the most common diseases ...

09.04.2018 – 13:00

Norgine

NHS England to Fund Endocuff Vision® for Cancer Screening Colonoscopies Bowel

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and ...

09.04.2018 – 09:30

Grünenthal Group

Grünenthal and KU Leuven join forces to develop an innovative non-opioid pain treatment

Aachen and Leuven, Belgium (ots) - Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the ...

05.04.2018 – 08:00

Debiopharm International SA

Kaiku Health raises EUR4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi

Lausanne, Switzerland and Helsinki, Finland (ots) - Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has closed a EUR4.4 million funding round. The investment was led by Debiopharm Innovation Fund SA and Tesi with ...

05.04.2018 – 07:01

UCB Pharma

UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

Brussels (ots/PRNewswire) - - Acquisition to strengthen UCB's genomics and epigenomics research platform to identify novel drug targets UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). The total cost of the transaction, ...

27.03.2018 – 14:04

Merck KGaA

Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine kinase inhibitor - First regulatory designation for tepotinib - SAKIGAKE ...

23.03.2018 – 19:03

TiGenix and Takeda

TiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Disease in Europe

Leuven, Belgium and Osaka, Japan (ots/PRNewswire) - - First allogeneic stem cell therapy to receive central marketing authorization approval in Europe - Alofisel offers a new treatment option for patients who do not respond to current available therapies and may be subject to numerous invasive surgeries[1] TiGenix ...

22.03.2018 – 12:02

Kanabo Research

Kanabo Research Signs Partnership Agreement with Jupiter Research

Rehovot, Israel (ots/PRNewswire) - Kanabo Research, a Tel-Aviv-based medical cannabis R&D company, announced that it has signed a partnership agreement with Jupiter Research, an innovative manufacturer of high-performance inhalation hardware and technology for plant based extracts. (Photo: https://mma.prnewswire.com/media/657554/KANABO_Mark_and_Avihu.jpg ) ...

20.03.2018 – 09:02

Mallinckrodt Plc.

Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation

Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...

19.03.2018 – 13:01

Novo Nordisk A/S

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Chicago (ots/PRNewswire) - Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their body weight.[1] An ...

14.03.2018 – 20:56

OxThera AB

OxThera Announces the Randomization of the First Patient Into its Phase III EPHEX Study With Oxabact

Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact. Study OC5-DB-02 (EPHEX) is a ...

14.03.2018 – 14:21

Kanabo Research

The Israeli Ministry of Health has Approved Kanabo Research's Medical Cannabis Vaporizer as a Medical Device

Rehovot, Israel (ots/PRNewswire) - Israel becomes the first country in the world to grant medical device approval for a medical cannabis vaporizer Kanabo Research, a Tel-Aviv-based medical cannabis R&D company, is pleased to announce that the Israeli Ministry of Health has granted initial approval as a medical device to its VapePod vaporizer product. This action makes Israel the first county in the world to grant medical device approval to a ...

07.03.2018 – 13:45

Campus Klinik an der Ruhr-Universität Bochum

Brain damage in newborns - unique index discovered / Head circumference determines brain damage in newborns!

Ein Dokument

28.02.2018 – 09:01

Royal Philips

Philips Launches Digital Ingenia Elition MR Solution, Delivering Premium Digital Image Quality up to 50% Faster [1]

Amsterdam (ots/PRNewswire) - Debuted at ECR 2018, the newest addition to Philips' digital MR solutions portfolio provides breakthrough in speed, improved patient experience and clinical confidence Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the newest addition to its digital Ingenia MR portfolio, the Ingenia Elition, a new 3.0T MRI solution. Integrating the latest innovations in systems, software and ...

27.02.2018 – 11:00

Hitachi Medical Systems Europe Holding AG

Hitachi Medical Systems Europe announces "ScanSync" - a new function for diagnostic ultrasound that reduces the burden on operators - which is to be supported by the "ARIETTA Prologue"

Vienna (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100012989?langid=2 - This function enables the operation of the diagnostic ultrasound system via auto detection of transducer movement. Hitachi Medical Systems Europe, a wholly owned subsidiary of Hitachi, ...

26.02.2018 – 17:54

Merck KGaA

Mavenclad (Cladribine Tablets) Receives First Approval in Latin America

Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years Merck, a leading science and technology ...

23.02.2018 – 14:01

Norgine

UK High Court of Justice Rules Endocuff® and Endocuff Vision® Patents and Design Rights to be Valid and Infringed

Amsterdam (ots/PRNewswire) - Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel's AmplifEYE® endoscopic ...

20.02.2018 – 15:02

InSightec

Israel Ministry of Health Includes INSIGHTEC's Focused Ultrasound Treatment for Medication-Refractory Essential Tremor as Part of Covered Health Services

Haifa, Israel and Miami (ots/PRNewswire) - INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MR-guided focused ultrasound (MRgFUS) announced today that the Neuravive focused ultrasound treatment will be a covered service for essential tremor patients in Israel. The ...

20.02.2018 – 13:31

Accuray

Accuray's European AERO Academy Meeting: Innovation and Safety in the Field of Advanced Radiotherapy - Patients Come First

Sunnyvale, Caliornia (ots/PRNewswire) - 2018 Accuray Conference Focused on Innovative Approaches for Advancing Patient Care, from Curative Treatment to Oligometastases and Palliation Accuray Incorporated (NASDAQ: ARAY) announced today highlights from its 2018 European AERO(TM) (Accuray Exchange in Radiation ...

19.02.2018 – 14:00

Debiopharm International SA

GenePOC launches its revogene(TM) instrument and GBS LB test in Canada

Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group(TM), is proud to announce the launch in its home market for the revogene instrument and the GenePOC(TM) GBS LB assay. About Group B Streptococcus (GBS) in Canada GBS is the leading cause of infection in infants worldwide with a fatality rate between 4-6%[1]. The SOGC guideline[2] recommends ...

16.02.2018 – 17:01

Takeda Pharmaceutical Company Limited

Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease Patients in Comparative Effectiveness Real-World Data Analysis

Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...

15.02.2018 – 14:31

Merck KGaA

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...

15.02.2018 – 09:00

Debiopharm International SA

Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections

Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...

12345678910Nächste